Headlines about ACASTI PHARM-TS (CVE:APO) have trended positive on Saturday, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by monitoring more than 6,000 news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. ACASTI PHARM-TS earned a daily sentiment score of 2.60 on their scale. InfoTrie also assigned headlines about the company an news buzz score of 4 out of 10, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Separately, B. Riley reissued a “buy” rating on shares of ACASTI PHARM-TS in a research note on Wednesday, August 28th.

ACASTI PHARM-TS (CVE:APO) last released its earnings results on Wednesday, November 13th. The company reported C($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of C($0.13) by C$0.03.

Read More: How to trade on quiet period expirations

Receive News & Ratings for ACASTI PHARM-TS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACASTI PHARM-TS and related companies with MarketBeat.com's FREE daily email newsletter.